David Einhorn’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$41.4M Sell
1,131,747
-1,020,922
-47% -$37M 1.16% 31
2026
Q2
$76.2M Hold
2,152,669
– – 1.95% 18
2026
Q1
$59.6M Buy
2,152,669
+83,360
+4% +$2.14M 1.87% 18
2025
Q4
$44.9M Sell
2,069,309
-206,220
-9% -$4.07M 1.58% 19
2025
Q3
$34.4M Sell
2,275,529
-2,275,528
-50% -$28.2M 1.35% 20
2025
Q2
$51.3M Sell
4,551,057
-890,110
-16% -$9.6M 2.21% 16
2025
Q1
$54.9M Buy
5,441,167
+170,100
+3% +$1.84M 2.78% 12
2024
Q4
$62.4M Sell
5,271,067
-36,973
-0.7% -$437K 3.21% 10
2024
Q3
$61.3M Buy
5,308,040
+497,080
+10% +$5.66M 2.55% 11
2024
Q2
$50.9M Buy
4,810,960
+620,470
+15% +$6.8M 2.49% 12
2024
Q1
$44.2M Buy
+4,190,490
New +$45.2M 2.02% 16

Other funds holding ROIV

David Einhorn's ROIV Position: Q3 2026 in Review

David Einhorn reduced its Roivant Sciences (ROIV) stake by 47% in Q3 2026, selling an estimated $37M and leaving 1,131,747 shares worth $41.4M. The position accounts for 1.16% of the portfolio, ranked #31.

David Einhorn first reported a position in ROIV in Q1 2024 and has held it in 11 quarters since. The position peaked at $76.2M in Q2 2026. 522 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • David Einhorn held 1,131,747 shares of Roivant Sciences worth $41.4M as of Q3 2026.
  • David Einhorn sold 1,020,922 Roivant Sciences shares in Q3 2026, an estimated $37M.
  • Roivant Sciences made up 1.16% of David Einhorn's portfolio in Q3 2026, its #31 holding.
  • David Einhorn first reported a position in Roivant Sciences in Q1 2024 and has held it in 11 quarters since.
  • David Einhorn's Roivant Sciences position peaked at $76.2M in Q2 2026.
  • 522 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on DME Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.